Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4125 - Realworld prospective data of small biopsy samples for tumor PD-L1 expression in non-small-cell lung cancer

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Kei Morikawa

Citation

Annals of Oncology (2018) 29 (suppl_8): viii670-viii682. 10.1093/annonc/mdy304

Authors

K. Morikawa, A. Tsunoda, T. Inoue, M. Mineshita

Author affiliations

  • Division Of Respiratory Diseases, St. Marianna University School of Medicine, 216-8511 - Kawasaki/JP

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4125

Background

PD-1 antibody has been effective in patients with PD-L1-positive advanced NSCLC. However, surgically resected specimens or core-needle biopsy samples were used to estimate drug potency in past clinical trials.

Methods

The aim is to prospectively investigate small sample reliability for NSCLC to determine the PD-L1 expression status. We prospectively enrolled patients who underwent diagnostic biopsy by any procedures (bronchoscopy, CT/US-guided core-needle) from 2017.3 to 2018.3. Pathologically confirmed NSCLC PD-L1 expression was evaluated in our institution using companion diagnostic PD-L1 IHC. We evaluated: 1) the total number of tumor cells and sample size; 2) compared PD-L1 expression for each procedure using tumor proportion score: TPS (50%≦, 1∼49%, <1%), 3) the concordance rate of PD-L1 expression status by biopsy and surgical materials.

Results

137 cases of PD-L1 expression were evaluated. 112 cases were sampled by bronchoscopy (98 TBBs using BF-1T260/P260F in 23/75 cases, 20 TBNAs), and 25 cases of CT or US-guided core-needle biopsy. The TPS (50%≦ / 1∼49% / <1% / undiagnosed) for total cases was 31/29/37/3% respectively which was similar to the past report. In histological subtype, TPS for adenocarcinoma (n = 82) were 28/27/43/2% and squamous cell carcinoma (n = 49) were 35/35/27/4% respectively. TPS for TBBs using BF-P260F (thin bronchoscopy) were 20/33/43/4% and TBBs using BF-1T260 (normal bronchoscopy) were 48/22/30/0%. TPS for TBNAs were 50/25/25/0% and CT or US-guided sample showed 37/21/37/5%. Four cases were not able to be diagnosed for TPS because we couldn’t obtain enough tumor cells (less than 100 tumor cells) for diagnosis of TPS. The concordance rate of PD-L1 expression status by biopsy and surgical materials was 83.3% for comparison of 24 cases.

Conclusions

Utilizing smaller samples to evaluate PD-L1 expression, the frequencies of TPS were comparable to past clinical trials which used larger samples for evaluating TPS. In this study, the larger samples showed higher PD-L1 expression than smaller samples due to their containing more squamous cell carcinoma cases or advanced stage. The concordance rate of PD-L1 expression for surgically resected tissue and biopsy sample was relatively good in our institution.

Clinical trial identification

UMIN000027030.

Legal entity responsible for the study

Kei Morikawa.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.